Carmustine Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg
Reference Brands: BiCNU (USA), Gliadel (USA)
Category:
Oncology Cancer Care
Carmustine is available in Injection
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Carmustine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Carmustine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Carmustine is a chemotherapeutic medication sold under the brand name BiCNU and other regional brands, primarily used as an alkylating agent in cancer treatment. Chemically classified as a nitrogen mustard β-chloro-nitrosourea compound, carmustine works by forming cross-links in DNA, preventing cancer cells from dividing and promoting cell death. It is widely used to treat various cancers, including brain tumors such as glioma, glioblastoma multiforme, medulloblastoma, and astrocytoma, as well as multiple myeloma, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma.
Carmustine is often used in combination with alkyl guanine transferase (AGT) inhibitors, such as O6-benzylguanine, which enhance its efficacy by blocking DNA repair pathways and increasing cancer cell sensitivity. Additionally, it is used as part of pre-transplant conditioning protocols in hematological stem cell transplantation, typically alongside fludarabine and melphalan, to reduce white blood cell counts and prepare patients for bone marrow transplant procedures.
For the treatment of brain tumors, carmustine is also available in biodegradable implantable wafers, marketed as Gliadel, which are placed under the skull during craniotomy. These implants provide controlled local release of the drug directly into the brain tissue, bypassing the blood-brain barrier and maximizing therapeutic effect while minimizing systemic exposure. Carmustine remains an essential tool in oncology for both systemic and localized cancer therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing